中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2014年
20期
38-39
,共2页
艾秀清%任云凤%朱相露%木妮热·木沙江
艾秀清%任雲鳳%硃相露%木妮熱·木沙江
애수청%임운봉%주상로%목니열·목사강
男性乳腺癌%放疗%治疗效果
男性乳腺癌%放療%治療效果
남성유선암%방료%치료효과
Male breast cancer%Radiation therapy%Treatment effect
目的:观察对男性乳腺癌术后患者实施放疗的治疗效果。方法21例男性乳腺癌患者,随机分为未放疗组和放疗组。未放疗组10例术后实施辅助化疗,对放疗组11例术后实施放疗。比较两组的生存率、复发率和治疗有效率。结果未放疗组10例治疗总有效率为70.00%,放疗组11例治疗总有效率为90.91%,放疗组高于未放疗组,差异有统计学意义(P<0.05)。放疗组放疗并发症的发生率为27.27%,随访发现,2例死亡,生存率为81.82%。3年内6例复发,复发率为54.55%;5例有远处转移,转移率为45.45%。结论放疗对男性乳腺癌术后患者的治疗效果较好,生存率较高,值得应用。
目的:觀察對男性乳腺癌術後患者實施放療的治療效果。方法21例男性乳腺癌患者,隨機分為未放療組和放療組。未放療組10例術後實施輔助化療,對放療組11例術後實施放療。比較兩組的生存率、複髮率和治療有效率。結果未放療組10例治療總有效率為70.00%,放療組11例治療總有效率為90.91%,放療組高于未放療組,差異有統計學意義(P<0.05)。放療組放療併髮癥的髮生率為27.27%,隨訪髮現,2例死亡,生存率為81.82%。3年內6例複髮,複髮率為54.55%;5例有遠處轉移,轉移率為45.45%。結論放療對男性乳腺癌術後患者的治療效果較好,生存率較高,值得應用。
목적:관찰대남성유선암술후환자실시방료적치료효과。방법21례남성유선암환자,수궤분위미방료조화방료조。미방료조10례술후실시보조화료,대방료조11례술후실시방료。비교량조적생존솔、복발솔화치료유효솔。결과미방료조10례치료총유효솔위70.00%,방료조11례치료총유효솔위90.91%,방료조고우미방료조,차이유통계학의의(P<0.05)。방료조방료병발증적발생솔위27.27%,수방발현,2례사망,생존솔위81.82%。3년내6례복발,복발솔위54.55%;5례유원처전이,전이솔위45.45%。결론방료대남성유선암술후환자적치료효과교호,생존솔교고,치득응용。
ObjectiveTo observe the treatment effect of postoperative radiotherapy on male breast cancer patients.MethodsSelected 21 male breast cancer patients for radiation therapy in our hospital and divied them into radiotherapy group(11 cases) and non-radiotherapy group(10 cases). Non-radiotherapy group given postoperative adjuvant chemotherapy, radiotherapy group given postoperative radiotherapy. Survival,recurrence, and treatment efficiency of two groups were compared.ResultsEffective rate of non-radiotherapy group(70%) was higher than radiotherapy group(90.91%), the difference was statistically significant(P<0.05). Incidence of complications in radiation radiation group was 27.27%, follow-up found 2 cases died, survival rate was 81.82%, 6 cases of recurrence within 3 years, recurrence rate was 54.55%; 5 patients with distant metastasis, transfer rate was 45.45%.ConclusionPostoperative radiotherapy treatment effect is good in patients with male breast cancer with high survival rate, so it is worthy of application.